Busy Month of Approvals: A Review of Oncology Drugs Approved in May in China and Abroad
By Xiaobin
The first half of 2020 will pass soon. Although foreign countries are still under the shadow of the COVID-19 pandemic, China’s situation is gradually stabilizing and improving through the concerted efforts of all to fight the pandemic. It is gratifying that there is no slacking in the approval of new anticancer drugs, whether in China or abroad. Many new drugs and therapies have been approved for marketing in May alone. Here is an overview of several representative important approvals in the oncology field for your reference.
Visit PharmaSources.com to read more:
Busy Month of Approvals: A Review of Oncology Drugs Approved in May in China and Abroad
CPhI China 2020 To Be Postponed to Dec. 16-18th,
Register as Visitor to the 20th Edition of CPhI China!
----------------------------------------------------------------------
Editor's Note:
To become a freelance writer of PharmaSources.com,
welcome to send your CV and sample works to us,
Email: [email protected].